Signal Transduction and Targeted Therapy

Article	Citations
Pyroptosis: mechanisms and diseases	1150
Inflammation and tumor progression: signaling pathways and targeted intervention	1091
The JAK/STAT signaling pathway: from bench to clinic	1029
The role of m6A modification in the biological functions and diseases	998
Microbiota in health and diseases	970
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities	844
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives	823
Therapeutic peptides: current applications and future directions	758
Pattern recognition receptors in health and diseases	738
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells	700
Viral vector platforms within the gene therapy landscape	688
Ferroptosis: mechanisms and links with diseases	682
Antibody drug conjugate: the “biological missile” for targeted cancer therapy	605
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets	586
Targeting PI3K/Akt signal transduction for cancer therapy	574
Copper homeostasis and cuproptosis in health and disease	494
Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity	448
Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics	443
Circulating tumor cells: biology and clinical significance	438
Targeting tumor-associated macrophages to synergize tumor immunotherapy	436
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy	424
Stem cell-based therapy for human diseases	421
Notch signaling pathway: architecture, disease, and therapeutics	414
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments	409
Macrophages in immunoregulation and therapeutics	409

A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome	407
KRAS mutation: from undruggable to druggable in cancer	391
SARS-CoV-2 Omicron variant: recent progress and future perspectives	391
Extracellular matrix and its therapeutic potential for cancer treatment	386
Lactate metabolism in human health and disease	385
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention	370
Osteoarthritis: pathogenic signaling pathways and therapeutic targets	367
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy	367
The signal pathways and treatment of cytokine storm in COVID-19	365
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development	364
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer	358
Targeting macrophages in cancer immunotherapy	354
Liquid–liquid phase separation in human health and diseases	341
Regulated cell death (RCD) in cancer: key pathways and targeted therapies	337
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer	328
G protein-coupled receptors: structure- and function-based drug discovery	323
Signaling pathways and targeted therapy for myocardial infarction	308
Wnt/β-catenin signaling in cancers and targeted therapies	297
Advances in COVID-19 mRNA vaccine development	290
The blood–brain barrier: Structure, regulation and drug delivery	289
mRNA-based therapeutics: powerful and versatile tools to combat diseases	284
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions	281
Targeting circular RNAs as a therapeutic approach: current strategies and challenges	281
Targeted protein degradation: mechanisms, strategies and application	280
Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches	280
Role of neuroinflammation in neurodegeneration development	279
Neoantigens: promising targets for cancer therapy	273
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1	272
The secretion profile of mesenchymal stem cells and potential applications in treating human diseases	269
Targeting integrin pathways: mechanisms and advances in therapy	268
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions	264
Inflammation and aging: signaling pathways and intervention therapies	256
The sirtuin family in health and disease	256
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy	255
NAD+ metabolism, stemness, the immune response, and cancer	248
Trends in insulin resistance: insights into mechanisms and therapeutic strategy	248
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	247
Radiotherapy combined with immunotherapy: the dawn of cancer treatment	242
Emerging new therapeutic antibody derivatives for cancer treatment	241
Mutations of MSH5 in nonobstructive azoospermia (NOA) and rescued via in vivo gene editing	236
From purines to purinergic signalling: molecular functions and human diseases	232
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy	231
Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents	229
COVID-19 vaccine development: milestones, lessons and prospects	226
Alternative splicing and cancer: a systematic review	222
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling	221
T cells in health and disease	214
Epigenetic regulation of aging: implications for interventions of aging and diseases	212
T cell receptor (TCR) signaling in health and disease	212
HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation	209

Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	209
Small molecule metabolites: discovery of biomarkers and therapeutic targets	208
Targeting TGFβ signal transduction for cancer therapy	207
Targeting p53 pathways: mechanisms, structures and advances in therapy	203
Protein kinase CK2: a potential therapeutic target for diverse human diseases	198
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets	198
SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance	197
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy	196
Roles and mechanisms of exosomal non-coding RNAs in human health and diseases	195
Mitochondrial dynamics in health and disease: mechanisms and potential targets	194
The Hippo signalling pathway and its implications in human health and diseases	193
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response	193
CRISPR/Cas9 therapeutics: progress and prospects	192
Targeting non-coding RNAs to overcome cancer therapy resistance	188
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial	183
Structural biology of SARS-CoV-2: open the door for novel therapies	183
SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration	181
Intercellular mitochondrial transfer as a means of tissue revitalization	180
Targeting fibrosis: mechanisms and clinical trials	178
Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway	177
SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2	175
The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives	174
Immunosenescence: molecular mechanisms and diseases	173
Nanomedicine in cancer therapy	171
Human organoids in basic research and clinical applications	167
Smart nanoparticles for cancer therapy	167
COVID-19 in early 2021: current status and looking forward	165
The BET family in immunity and disease	164
The biological applications of DNA nanomaterials: current challenges and future directions	163
Signal pathways of melanoma and targeted therapy	160
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics	160
Recent progress in targeted delivery vectors based on biomimetic nanoparticles	159
Vaccine adjuvants: mechanisms and platforms	158
Kidney fibrosis: from mechanisms to therapeutic medicines	157
Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies	155
AlphaFold2 and its applications in the fields of biology and medicine	153
Signaling pathways in obesity: mechanisms and therapeutic interventions	153
Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease	151
HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19	150
Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events	149
Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion	149
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics	148
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)	146
Spinal cord injury: molecular mechanisms and therapeutic interventions	146
NF-κB in biology and targeted therapy: new insights and translational implications	144
Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations	142
Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention	141
Artificial intelligence in cancer target identification and drug discovery	139
Bioactive potential of natural biomaterials: identification, retention and assessment of biological properties	139
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer	137
Molecular regulations of circadian rhythm and implications for physiology and diseases	136
Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials	136
Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis	134
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends	134
Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota	134
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies	133
Signaling pathways in rheumatoid arthritis: implications for targeted therapy	132
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	131
Inflammasomes as therapeutic targets in human diseases	131
RNA modifications: importance in immune cell biology and related diseases	130
The STING1 network regulates autophagy and cell death	129
A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair	128
Signaling pathways of chronic kidney diseases, implications for therapeutics	127
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients	125
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	125
The glycosylation in SARS-CoV-2 and its receptor ACE2	122
Mesenchymal stem cell-derived small extracellular vesicles mitigate oxidative stress-induced senescence in endothelial cells via regulation of miR-146a/Src	122
Signaling pathways and intervention therapies in sepsis	122
Colorectal liver metastasis: molecular mechanism and interventional therapy	120
Engineered exosomes from different sources for cancer-targeted therapy	120
The mitophagy pathway and its implications in human diseases	119
Targeting ferroptosis opens new avenues for the development of novel therapeutics	118
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy	118
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy	117
Cytosolic DNA sensing by cGAS: regulation, function, and human diseases	115
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer	115
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis	114
The role of histone modifications: from neurodevelopment to neurodiseases	114
Natural killer cell homing and trafficking in tissues and tumors: from biology to application	114
Monkeypox: epidemiology, pathogenesis, treatment and prevention	113

Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression	113
Ketogenic diet alleviates colitis by reduction of colonic group 3 innate lymphoid cells through altering gut microbiome	112
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer	111
Omicron: increased transmissibility and decreased pathogenicity	110
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions	109
Ketogenic diets inhibit mitochondrial biogenesis and induce cardiac fibrosis	108
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)	108
ACE2-independent infection of T lymphocytes by SARS-CoV-2	108
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages	106
Alternative approaches to target Myc for cancer treatment	106
RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-κB hyper-activation and inflammation	104
Functional hair follicle regeneration: an updated review	104
TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases	104
Extracellular vesicles as tools and targets in therapy for diseases	103
Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions	102
Targeting epigenetic regulators to overcome drug resistance in cancers	102
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19	99
Oncolytic virotherapy: basic principles, recent advances and future directions	99
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies	98
Spatiotemporal control of CRISPR/Cas9 gene editing	97
NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1	97
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management	96
Patient-derived xenograft models in cancer therapy: technologies and applications	96
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)	96
ALOX15-launched PUFA-phospholipids peroxidation increases the susceptibility of ferroptosis in ischemia-induced myocardial damage	95
Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine	95
Clinical applications of stem cell-derived exosomes	95
Targeting lysosomes in human disease: from basic research to clinical applications	94
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines	94
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	93
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	93
Signaling pathways and therapeutic interventions in gastric cancer	93
Amino acid metabolism in health and disease	92
Liquid–liquid phase separation in tumor biology	91
Ribosome biogenesis in disease: new players and therapeutic targets	90
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective	90
Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins	90
SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies	89
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity	88
Clinical and translational values of spatial transcriptomics	87
SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules	87
The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys	87
Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment	86
Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy	84
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets	84
Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes	84
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications	83
GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages	83
Emerging phagocytosis checkpoints in cancer immunotherapy	83
Pathogenesis of allergic diseases and implications for therapeutic interventions	83
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets	81
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	80
m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance	79
Cryo-EM advances in RNA structure determination	78
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials	78
Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer	78
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients	77
Astrocytes in human central nervous system diseases: a frontier for new therapies	77
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials	76
Targeted therapy for head and neck cancer: signaling pathways and clinical studies	76
Neurological complications and infection mechanism of SARS-CoV-2	76
The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing	75
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia	75
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications	75
Dynamic blood single-cell immune responses in patients with COVID-19	75
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need	75
Major depressive disorder: hypothesis, mechanism, prevention and treatment	75
POD Nanozyme optimized by charge separation engineering for light/pH activated bacteria catalytic/photodynamic therapy	74
Omicron adopts a different strategy from Delta and other variants to adapt to host	74
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets	73
Targeting polarized phenotype of microglia via IL6/JAK2/STAT3 signaling to reduce NSCLC brain metastasis	72
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies	72
Temporal and spatial cellular and molecular pathological alterations with single-cell resolution in the adult spinal cord after injury	72
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants	72
The key roles of cancer stem cell-derived extracellular vesicles	72
Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota	71
N501Y mutation imparts cross-species transmission of SARS-CoV-2 to mice by enhancing receptor binding	71
Cardiomyocyte-specific knockout of ADAM17 ameliorates left ventricular remodeling and function in diabetic cardiomyopathy of mice	71
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	71
Therapeutic cancer vaccines: advancements, challenges and prospects	70
TGF-β signaling in health, disease and therapeutics	70
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma	69
A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response	69
Application of 3D bioprinting in the prevention and the therapy for human diseases	69
Small molecules in the treatment of COVID-19	68
Mesenchymal stem cell therapy for severe COVID-19	67
Not only ACE2—the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19	67
Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3	66
Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19	65
Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster	65
AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma	64
Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects	64
Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence	63
COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors	63
Dietary regulation in health and disease	62